Synergy Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SGYP) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.0352-Week Range N/AVolumeN/AAverage Volume6.08 million shsMarket Capitalization$7.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.Read More SGYP Stock News HeadlinesMay 9, 2023 | investing.comSynergy Pharmaceuticals Inc Unit (SGYPU)April 12, 2023 | forbes.comMarket Factor Synergy Signals Exciting Growth For Digital PathologyDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.March 29, 2023 | bbc.co.ukDifferent resistorsMarch 28, 2023 | bbc.co.ukMains cablesMarch 28, 2023 | bbc.co.ukEnergy changes in brakingDecember 18, 2022 | thestreet.comSynergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson InvestmentSeptember 13, 2022 | investing.comJiangxi Synergy Pharmaceutical Co Ltd (300636)December 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.May 16, 2022 | seekingalpha.comSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call TranscriptJanuary 18, 2022 | thestreet.comHere's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying TodayDecember 2, 2021 | finanznachrichten.deOKYO Pharma LTD: OKYO Pharma Limited: Directorate ChangeOctober 21, 2020 | markets.businessinsider.comNews for Synergy Pharmaceuticals Inc.August 20, 2020 | markets.businessinsider.comSynergy Pharmaceuticals Inc. - ProfileJuly 23, 2020 | sg.finance.yahoo.comSynergy Pharmaceuticals (SGYP) Surges: Stock Moves 12.1% HigherMay 23, 2020 | www.bloomberg.comCORRECTING and REPLACING Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business UpdateMay 23, 2020 | www.bloomberg.comSynergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access WinsMarch 18, 2020 | www.marketwatch.comIdentify IBS Treatment Market Regional Growth Drivers Electrifying Development PaceApril 12, 2019 | finance.yahoo.comFINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLDApril 11, 2019 | feeds.benzinga.comFRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmApril 10, 2019 | finance.yahoo.comDEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmApril 9, 2019 | finance.yahoo.comDEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmApril 9, 2019 | finance.yahoo.comSGYP & MHLD - Class Action Bronstein, Gewirtz & Grossman, LLCApril 8, 2019 | finance.yahoo.comSYNERGY INVESTORS APRIL 12th DEADLINE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.; Encourages Investors With Losses In Excess of $100K to Contact the Firm – SGYPApril 7, 2019 | feeds.benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYPApril 5, 2019 | finance.yahoo.comClass Action Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLDApril 3, 2019 | finance.yahoo.comClass Action Reminder Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLDSee More Headlines Receive SGYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2018Today12/02/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGYP CUSIP87163930 CIK1347613 Webwww.synergypharma.com Phone212-297-0020FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-224,330,000.00 Net Margins-332.11% Pretax MarginN/A Return on EquityN/A Return on Assets-118.14% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.38 Sales & Book Value Annual Sales$16.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares248,040,000Free FloatN/AMarket Cap$7.44 million OptionableOptionable Beta4.94 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Troy Hamilton Pharm.D. (Age 47)CEO & Director Mr. Gary G. Gemignani (Age 54)Exec. VP & CFO Gem Gokmen HopkinsVP of Investor Relations and Corp. CommunicationsMs. Pamela CebulskiSr. VP of MarketingMs. Marianne JacksonSr. VP of Sales & Market AccessKey CompetitorsFortress BiotechNASDAQ:FBIOCatalyst BiosciencesNASDAQ:CBIORegulus TherapeuticsNASDAQ:RGLSMolecular TemplatesNASDAQ:MTEMApplied Molecular TransportNASDAQ:AMTIView All Competitors SGYP Stock Analysis - Frequently Asked Questions How were Synergy Pharmaceuticals' earnings last quarter? Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to analysts' expectations of $15.65 million. What other stocks do shareholders of Synergy Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and This page (NASDAQ:SGYP) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.